Short answer
MESA LABORATORIES INC /CO/ (MLAB) filed its Q4 2025 10-Q quarterly report on Feb 3, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $65M with net income of $4M.
Q4 2025 key financials · XBRL
- Revenue
- $65M
- +7.2% QoQ
- Net income
- $4M
- +46.6% QoQ
- Operating margin
- 12.2%
- Gross margin
- 64.2%
- EPS (diluted)
- $0.65
- +44.4% QoQ
Source: XBRL data from the MESA LABORATORIES INC /CO/ (MLAB) Q4 2025 10-Q on SEC EDGAR. USD.
MESA LABORATORIES INC /CO/ Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Nine-month revenue $[not provided], up 3.7% YoY, driven by BPD, Sterilization and Disinfection Control, and Calibration Solutions
- Clinical Genomics worst-performing division, with revenue declines from China trade tensions and macroeconomic weakness
- Gross margin impact: tariffs and weaker USD reduced year-to-date margin approximately 0.8 percentage points
- Operating expenses up 2.8% YoY, with higher China receivable allowances, personnel costs, stock compensation, and severance
- China headwinds expected through fiscal 2026 and most likely into fiscal 2027
Risk Factors
- No material changes disclosed from March 31, 2025 Form 10-K risk factors
- Share-repurchase authorization risk, with 162,486 shares remaining under the plan
- Equity-plan tax-withholding share transfers, with no shares purchased under the public program
- No new director or officer Rule 10b5-1 trading plans during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MESA LABORATORIES INC /CO/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.